Video
Please note that the English version of this text has been prepared with the assistance of AI, and in some instances, it may not have been subsequently reviewed or edited by the authors.
Description
CAR-T therapy has fundamentally changed cancer treatment, but its manufacturing remains expensive and technologically very complex, mainly due to the use of viral vectors.
In project FusionX, we are developing a membrane fusion-based delivery technology that enables efficient T cell modification without the use of viruses. By designing novel, membrane-active lipids capable of directly fusing with the cell membrane, we aim to deliver therapeutic material directly into the cytosol while simplifying the manufacturing process and reducing technological barriers.
The Achievable Results
Develop an efficient, non-viral vector-based T-cell modification technology, based on membrane fusion, that simplifies CAR-T therapy production and enhances its accessibility.
The Anticipated Benefit
To make modern cancer therapies safer, cheaper, and more accessible to patients, while reducing the risks and costs associated with complex biotechnologies.
The Allocated Funding
190,000 EUR on 03/01/2026.
Team
Dr. Mahuya Pakhira
Researcher 
Katrīna Freimane
Laboratory Technician Gallery
